RCT for the Chinese Medicine in Treating Hypercholesterolemia
ConditionHypercholesterolemia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorChinese University of Hong Kong
About this trial
This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.
Eligibility criteria
Qualifiers
Age 18-80 years old, any gender;
LDL-C level of 4.1 mmol/L or above (no statin therapy during the screening period);
Be able to maintain a more consistent lifestyle and eating habits throughout the study;
Have a fixed residence and are not expected to move or travel for 8 weeks;
Disqualifiers
Taking drugs that may affect lipid metabolism (such as steroids, sleeping pills, and psychotropic drugs);
Alcohol or drug abuse within the last 3 months;
Known liver function or renal dysfunction;
History of severe cardiovascular and cerebrovascular diseases; or history of psychiatric illness;
Trial design
Treatments tested in this trial
- Dachaihu Decoction combined Erzhiwan with variation
- Placebo granules
Treatment groups
70 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov